Tempus AI Inc. TEM, a synthetic intelligence-powered precision medication options supplier, which was listed on exchanges in June 2024 has seen main funds investing within the firm in the course of the fourth quarter of the 12 months.
What Occurred: Tempus AI offers a two-pronged strategy to healthcare. The primary is an AI-driven precision medication for personalised affected person care, and the second is a parallel engine for locating, growing, and delivering optimum therapeutics.
Over the three-quarters of 2024 for which the corporate has been listed, it has seen the variety of filings develop to 174 from 89. Whereas, the variety of shares, excluding choices has additionally elevated considerably.
Listed here are just a few key highlights of Tempus AI’s fourth-quarter changes within the portfolios of varied funds by means of its 13F SEC filings.
- Cathie Wooden‘s ARK Funding Administration LLC elevated its place within the firm by 132% from the third and 956% from the second quarter, with its present holdings within the firm valued at $186.343 million.
- JPMorgan Chase & Co. added a staggering 43424% or 1,650,096 shares within the fourth quarter, whereas UBS Group AG elevated its stake by 6524% or 786,025 shares in the identical interval.
- Barclays PLC additionally added 3675% or 34,031 shares of the corporate to its portfolio, whereas Goldman Sachs Group Inc. and Morgan Stanley hiked their stakes by 129% and 40%, respectively.
- BlackRock Inc., Financial institution of New York Mellon Corp., and Ken Griffin‘s Citadel Advisors LLC took contemporary positions in Tempus AI and 70 different funds in the course of the quarter.
| Firm | Holdings (as of Sept. 30) | Holdings (as of Dec. 31) | Change (in %) | Worth As Of Dec. 31 |
| ARK Funding Administration LLC | 2,378,157 | 5,519,644 | 132% | $186.343 million |
| JPMorgan Chase & Co. | 3,800 | 1,653,896 | 43424% | $55.835 million |
| UBS Group AG | 12,049 | 798,074 | 6524% | $26.942 million |
| Goldman Sachs Group Inc. | 26,687 | 61,026 | 129% | $1.107 million |
| Morgan Stanley | 190,215 | 265,302 | 40% | $8.956 million |
| Barclays PLC | 926 | 34,957 | 3675% | $1.180 million |
| BlackRock Inc. | 0 | 445,896 | 0% | $15.053 million |
| Financial institution of New York Mellon Corp. | 0 | 47,823 | 0% | $1.614 million |
| Citadel Advisors LLC | 0 | 131,800 | 0% | $4.449 million |
See Additionally: Billionaire Ray Dalio’s Bridgewater Trims Holdings In 6 Of ‘Magnificent 7’ Shares Amid Valuation Considerations, Provides This Automotive Inventory After 3 Years
Why It Issues: Whereas filings and share counts grew considerably, the worth of each shares and choices skilled fluctuations and finally decreased within the fourth quarter.
The info reveals notable developments throughout filings, shares, and their related values from the second quarter to the fourth quarter of 2024.
Indicating fewer possibility bets, the worth of choices, which peaked at $101 million within the third quarter, fell to $79.5 million within the fourth. Nevertheless, regardless of the rise in frequent shares in the course of the fourth quarter, the entire worth of shares (excluding choices) decreased from $2.12 billion to $1.74 billion.
| Interval | Filings | Shares, Excl. Choices | Worth, Excl. Choices | Choices Worth |
| 2024 This fall | 174 | 51.7 M | $1.74 B | $79.5 M |
| 2024 Q3 | 118 | 37.6 M | $2.12 B | $101 M |
| 2024 Q2 | 89 | 42.6 M | $1.49 B | $12.9 M |
Worth Motion: Tempus AI dropped 8.37% on Tuesday and recovered 1.21% throughout after-hours buying and selling, contrasting with a slight 0.076% dip within the Constancy NASDAQ Composite Index ETF ONEQ, which tracks the Nasdaq Composite index. Regardless of this current fall, TEM stays up 139.27% on a year-to-date foundation and 103.60% since its itemizing in June 2024.
Benzinga tracks 11 analysts with a median worth goal of $59.6 for the inventory, reflecting a “purchase” ranking. Estimates vary broadly from $44 to $74. Latest scores from TD Cowen, Loop Capital, and Needham common $60.67, suggesting a possible 26.85% draw back.
Learn Subsequent:
Photograph courtesy: Tempus
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
